Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: A comparison of two aromatase inhibitors to megestrol acetate

Anti-Cancer Drugs

Volumn 11, Issue 7, 2000, Pages 591-601

  Dranitsaris, George ^a,b   Leung, Pauline ^a   Mather, Jennifer ^a   Oza, Amit ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anastrozole; Breast cancer; Cost analysis; Letrozole; Megestrol acetate

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; DOCETAXEL; ESTROGEN RECEPTOR; LETROZOLE; MEGESTROL ACETATE; PACLITAXEL; VOROZOLE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST UTILITY ANALYSIS; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CANADA; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MEGESTROL ACETATE; NITRILES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; TRIAZOLES;

EID: 0033805663     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200008000-00012     Document Type: Article

References (31)

1. On the treatment of inoperable cases of carcinoma of the mammal
2. Emerging role of aromatase inhibitors in the treatment of breast cancer
3. The control of breast cancer: The role of tamoxifen
4. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with MA in postmenopausal women with advanced breast carcinoma
5. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with MA in postmenopausal patients with advanced breast cancer
6. The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
7. Letrozole, a new aromatase inhibitor for advanced breast cancer: Double blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
8. Letrozole, a new aromatase inhibitor: Randomized trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethamide in postmenopausal women with advanced breast cancer
9. Pharmacoeconomic applications of metaanalysis for single groups using antifungal onychomycosis lacquers as an example
10. Meta-analysis in clinical trials
11. Utility approach to measuring health-related quality of life
12. Canadian guidelines for economic evaluation of pharmaceuticals
13. The role of cost-effectiveness analysis in health and medicine
14. Double-blind, randomized, multicentre endocrine trial comparing letrozole doses, in postmenopausal breast cancer patients
15. Fadrozole versus megestrol acetate: A double-blind randomized trial in advanced breast cancer
16. High versus standard dose MA in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association
17. MA and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group phase III trial
18. Formestane versus MA in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomized cross over trial of second line hormonal treatment
19. A randomized comparison of MA and medroxyprogesterone acetate in patients with advanced breast cancer
20. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer
21. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma
22. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin
23. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial
24. 5-fluorouracil, adriamycin, cyclophosphamide (FAC) vs 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer
25. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advance breast cancer
26. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: Superiority of doxorubicin
27. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
28. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
29. A phase III trial comparing AT to AC as first line chemotherapy for metastatic breast cancer
30. Overall survival advantage to simultaneous chemotherapy plus humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer
31. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic